| Ident. | Authors (with country if any) | Title |
|---|
| 000488 |
Benjamin Dehay [France] ; Mathieu Bourdenx [France] ; Philippe Gorry [France] ; Serge Przedborski [États-Unis] ; Miquel Vila [Espagne] ; Stephane Hunot [France] ; Andrew Singleton [États-Unis] ; C. Warren Olanow [États-Unis] ; Kalpana M. Merchant [États-Unis] ; Erwan Bezard [France] ; Gregory A. Petsko [États-Unis] ; Wassilios G. Meissner [France] | Targeting α-synuclein for treating Parkinson’s disease: mechanistic and therapeutic considerations |
| 000B11 |
Anthony H. V. Schapira [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; J. Timothy Greenamyre [États-Unis] ; Erwan Bezard [France] | Movement disorders 3: Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives |
| 000E62 |
Erwan Bézard [France] ; C. Warren Olanow [États-Unis] ; José A. Obeso [Espagne] | Levodopa–induced dyskinesias in the absence of nigrostriatal degeneration |
| 000E80 |
C. Warren Olanow [États-Unis, Italie] ; Karl Kieburtz [États-Unis] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Anthony H. Schapira [Royaume-Uni] ; Murat Emre [Turquie] ; Helena Nissinen [Finlande] ; Mika Leinonen [Suède] ; Fabrizio Stocchi [Italie] | Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease |
| 001242 |
Andrew Lees [Royaume-Uni] ; Stanley Fahn [États-Unis] ; Karla M. Eggert [Allemagne] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; Federico Micheli [Argentine] ; M. Maral Mouradian [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Eduardo Tolosa [Espagne] ; David Squillacote [États-Unis] ; Dinesh Kumar [États-Unis] | Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease |
| 001B84 |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
| 001D14 |
C. Warren Olanow [États-Unis] ; O. Rascol [France] | The delayed-start study in Parkinson disease: Can't satisfy everyone |
| 002217 |
C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Robert Hauser [États-Unis] ; Paul D. Feigin [Israël] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; William Langston [États-Unis] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne] | A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease |
| 002373 |
Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Placebo influences on dyskinesia in Parkinson's disease |
| 002432 |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
| 002670 |
Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial |
| 003A60 |
C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] | Continuous dopamine-receptor stimulation in early Parkinson's disease |
